On November 21, 2024, the Alliance for Eye and Vision Research (AEVR) hosted an enlightening Congressional Briefing on Thyroid Eye Disease (TED). This event brought together policymakers, leading experts, and patient advocates to discuss advancements in TED research and the urgent need for improved treatments and funding support.
The briefing featured a dynamic panel of speakers who each shared unique insights into TED and its management. Dr. Collynn Woeller, an Assistant Professor at the University of Rochester Medical Center, shared her expertise on the underlying mechanisms of TED and highlighted the importance of continued research to advance treatment options.
Adding a powerful personal perspective, Dr. Nathaniel Jellinek, a TED patient advocate, recounted his own journey with the condition, including his experience with high-dose steroids, IV infusions, and the challenges of accessing effective treatments like Teprotumumab. His story underscored the need for legislative action to break down barriers to treatment and support patients dealing with this life-altering autoimmune disease.
The discussion covered critical topics such as the mental health challenges associated with TED, the importance of early diagnosis and intervention, and the role of research innovation in improving patient outcomes. The speakers also emphasized the need for sustained federal research funding to address the complexities of TED and provide patients with better treatment options.
We extend our sincere gratitude to our sponsors—Amgen, the Association for Research in Vision and Ophthalmology (ARVO), Research to Prevent Blindness, and the Vision Health Advocacy Coalition—for their generous support. Their commitment to advancing eye health and TED research made this impactful event possible.
If you missed the briefing, you can still watch the full event by following this link to our YouTube channel. Together, we can drive progress in TED research, improve treatment access, and support those affected by this challenging condition.
